FDA Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Entrectinib
FDA Grants Accelerated Approval to Mosunetuzumab-axgb for R/R Follicular Lymphoma
FDA Approves FoundationOne Liquid CDx for Some Tyrosine Kinase Inhibitors in NSCLC
FDA Approves Additional Indication for Pemetrexed in Combination
The Innovation Center Releases EOM Factsheets
FDA Approves Pafolacianine for Lung Cancer Surgery
FDA Updates Capecitabine Indications and Dosing Regimens
FDA Grants Accelerated Approval to Adagrasib for KRAS G12C-Mutated NSCLC
FDA Grants Approval to Atezolizumab for Alveolar Soft Part Sarcoma
FDA Approves a New Dosing Regimen for Asparaginase Erwinia Chrysanthemi
Roche Receives FDA Approval for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay
FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx
FDA Approves Brentuximab Vedotin + Chemo for Pediatric Patients with Hodgkin’s Lymphoma
FDA Approves Tremelimumab with Durvalumab + Chemotherapy for Metastatic NSCLC
FDA Approves Cemiplimab + Chemotherapy for NSCLC
Calendar Year 2023 Medicare Physician Fee Schedule Released
FDA Approves Teclistamab for Relapsed or Refractory Multiple Myeloma
FDA Approves Tremelimumab in Combination with Durvalumab for Unresectable HCC
FDA Grants Accelerated Approval to Futibatinib for Cholangiocarcinoma
FDA Approves Bevacizumab-adcd for Six Types of Cancer
FDA Expands Selpercatinib Approval for RET Fusion-Positive Solid Tumors
Foundation Medicine Announces Call for Grants
FDA Approves Eflapegrastim for Chemo-Induced Neutropenia
FDA Approves Durvalumab + Gemcitabine for Biliary Tract Cancer
GSK Shares Plans to Voluntarily Withdraw Niraparib
FDA Approves Pemigatinib for MLNs with FGFR1 Rearrangement
CMS Delays Radiation Oncology Model For Further Rulemaking
FDA Approves Ibrutinib for Pediatric Patients with Chronic Graft-Versus-Host Disease
FDA Approves Guardant360 CDx for HER2-Mutant NSCLC
FDA Approvees Fam-Trastuzumab Deruxtecan-nxki for HER2-Mutant NSCLC
